That trial is expected this month.
According to the April 22, 2008, issue of Bloomberg News, Kamie Kendall took Accutane for a total of 12 months over a six-year period beginning in 1997 for persistent acne that refused to respond to antibiotics. During that time, the plaintiff developed constant diarrhea and rectal bleeding, requiring the Salt Lake City clerical worker to vacate her bowels 20 times a day or more. The onset of Accutane inflammatory bowel disease, allegedly at the hands of Accutane, eventually required various surgical procedures to Kendall's intestine.
READ MORE ACCUTANE IBD LEGAL NEWS
It was reported by Courtroom View Network (CVN) that the Appellate Division of the New Jersey Superior Court vacated the Kendall trial via an unpublished opinion and ordered a new trial so that Hoffman-La Roche could provide quantitative information to the jury relating to the number of Accutane users and the background rate of IBD, reportedly in an effort to provide focus on the manufacturer's efforts to monitor the risk of harm.
A previous Accutane IBD trial that wound up in a retrial along similar lines proved a win for the plaintiff. In that case—McCarrell v. Hoffman-La Roche—the Accutane colitis plaintiff prevailed.